1. DRAP’s Regulatory Mandate
The Drug Regulatory Authority of Pakistan (DRAP) was established under the DRAP Act 2012 as the single federal authority for pharmaceutical, biological, and medical device regulation. DRAP oversees product registration, manufacturing facility licensing, and market authorization — processes that directly intersect with intellectual property rights.
2. Patent Linkage and Market Authorization
Pakistan currently does not implement formal patent linkage between DRAP registration and IPO-P patent databases. This means generic manufacturers can obtain DRAP registration for a product that is still under a valid patent, shifting the enforcement burden entirely to the patent holder. Key implications:
- Innovator companies must file for patent term extension before expiry to maintain exclusivity.
- Data exclusivity protections for clinical trial data exist for 5 years under DRAP guidelines.
- Counterfeit and substandard medicines enforcement requires coordinated action between DRAP, FIA, and IPO-P.
3. Strategy for Pharmaceutical Market Entry
A robust market entry strategy requires filing patents with IPO-P early, coordinating DRAP registration timelines with patent lifecycles, and engaging specialized IP counsel familiar with both DRAP administrative procedures and civil court enforcement mechanisms for patent infringement.